Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

122.94 +2.41 (+2.00%)
Streaming Delayed Price Updated: 11:13 AM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

This Company's 18-Month CBD Stability Achievement Could Hint Towards Expansion Goals As It Plans To Release First Commercial UST System In 2022
Photo by Kindel Media from Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Does This Company's Recent CBD Breakthrough Earn It A Spot In The Guinness World Records?
Photo by CBD Infos on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
New Psychedelics ETF Launches On NYSE Arca
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)... 
Via Benzinga
The "Cannabis 50" List For 2021 Is Out, Is Your Favorite Company On It?
MGO (Macias Gini and O’Connell LLP), a leader in accounting, tax, audit and advisory solutions for the cannabis and hemp industries has released its 3rd annual “Cannabis 50” list. 
Via Benzinga
Jim Cramer Shares His Thoughts On ArcBest, Ulta Beauty And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes ArcBest Corporation (NASDAQ: 
Via Benzinga
Analyst Ratings For Jazz Pharmaceuticals
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed th... 
Via Benzinga
Zogenix Nabs $1.9 Billion Takeover As Epilepsy Drug Piques UCB Interest
The deal includes a CVS tied to Fintepla's next potential approval. 
Via Investor's Business Daily
Report: Global Cannabis Beverages Market Expected To Reach $2B By 2026
As the COVID-19 pandemic continues, the global market for cannabis beverages estimated at $799.8 million 2020, is projected to reach a revised... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company... 
Via Benzinga
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
Via AB Newswire
A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year.... 
Via Benzinga
5 Stocks To Watch For January 4, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on... 
Via Benzinga
Ten Biggest Weed Stories Of 2021: Big Pharma, Delta-8, Tech, Silicon Valley, MSOs, Politics And More
This article was originally published on WeedWeek and appears here with... 
Via Benzinga
5 Themes That Will Drive The Cannabis Sector Higher In 2022
2021 was a period of strong growth for the global cannabis market and we expect the cannabis sector to build on its success in 2022. 
Via Talk Markets
Jazz Pharmaceuticals Begins Enrollment For Clinical Trial To Evaluate JZP150 For Adults With PTSD
Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced Thursday that it has enrolled the first patient in its Phase 2 clinical trial evaluating the safety and... 
Via Benzinga
Jazz Pharmaceuticals: Debt Overview
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) rose by 0.8% on Wednesday. Before having a look at the importance of debt, let us look at how much debt Jazz Pharmaceuticals... 
Via Benzinga
Corporate Cannabis Takeover? Assessing 5 Big Industries Already At The Table
This article was originally published on The Bluntness, and ... 
Via Benzinga
A Look Into Jazz Pharmaceuticals Debt
Over the past three months, shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) fell by 6.85%. Before we understand the importance of debt, let us look at how much debt Jazz... 
Via Benzinga
10 Biggest Price Target Changes For Monday
JP Morgan raised the price target on Public Storage (NYSE: 
Via Benzinga
The Week In Cannabis: Pfizer, Visa, $730M+ In Financings, Malta, EU, Columbia Care, MedMen, Uruguay And More
Below is a recap of the main news related to the cannabis industry and markets for the week of December 13, 2021. 
Via Benzinga
10 Biggest Price Target Changes For Friday
Piper Sandler boosted Accenture plc (NYSE:ACN) pric... 
Via Benzinga
7 Meme Stocks to Buy on Their Market Slump and Rebound
These seven meme stocks suffered downturns recently, but they have the appropriate catalysts to move upward in the near term. 
Via InvestorPlace
Are Cannabinoids the Next Frontier of Pharmaceuticals? This Company Thinks So and Wants to Lead the Pack
Photo by Michael Longmire on... 
Via Benzinga
How Pfizer Is Getting Into Cannabis With $6.7B Arena Pharma Deal
The two publicly-traded companies confirmed Monday that they have signed a definitive agreement under which Pfizer will acquire all outstanding shares of Arena for $100 per share in an all-cash... 
Via Talk Markets
Topics Cannabis
How Pfizer Is Getting Into Cannabis With $6.7B Arena Pharma Deal
Pharmaceutical giant Pfizer Inc. (NYSE:PFE) is e... 
Via Benzinga
Topics Cannabis
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) revealed initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze (asparaginase... 
Via Benzinga
Jupiter Wellness Just Reported A Big Move In Pharma
Image provided by Jupiter Wellness of their new lab. The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content... 
Via Benzinga
3 High-Growth Stocks That Are Screaming Buys in December
Now is a good time to be greedy and buy up these depressed stocks. 
Via The Motley Fool
Got $5,000? Buy These 3 Hot Pot Stocks Immediately
There might not be a better time to buy these three cannabis stocks than right now. 
Via The Motley Fool
Topics Cannabis
EXCLUSIVE: Cannabis-Based Drug Approved For Cancer Treatment In Peru
Cannabis-based drug Sativyl has been approved as a treatment for cancer-related pain in Peru. 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.